Purchase Order W81XWH21P0106
Award Date
7/26/21
Potential Completion Date
2/25/22
Potential Value
$250K
Federal Agency
Medical Command
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
20
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $167,496.80 STTR Phase I contract awarded by the Department of the Army Materiel Command Research Development and Engineering Command to the minority-owned small business Zymeron Corporation. The contract is for research and development of innovative biotechnology solutions, including technologies related to protein degradation, antibacterials, antivirals, and drug delivery systems. Zymeron has experience providing medical research, engineering services, IT solutions, and biotech...
This contract was awarded by the Department of the Army Materiel Command TACOM Life Cycle Management Command to Zymeron Corporation, a minority-owned small business. The contract is for Phase I SBIR (Small Business Innovation Research) research, with a firm fixed-price contract type and a potential value of $162,482.83. Zymeron is a biotechnology company that focuses on developing innovative technologies in areas such as protein degradation, antibacterials, antivirals, and drug delivery systems....
This is a $167,495.16 firm fixed-price contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Zymeron Corporation, a minority-owned small business research and development firm, under the Small Business Innovation Research (SBIR) program. The contract supports Phase I research and development of small molecule metal chelate cap-endo inhibitors as broad-spectrum antiviral treatments targeting bunyaviruses. The research is being...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Health Agency (DHA) to Zymeron Corporation, a minority-owned small business located in Research Triangle Park, North Carolina. The $2,999,998.63 fixed-price contract is for the "Development for ShockDefender Against Hemorrhagic Shock," which supports the DHA's medical research and development efforts. The contract was set aside for small businesses and will be performed in Research Triangle...
Zymeron Corporation has been awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Zymeron will develop a novel nanoparticle delivery system to elicit a potent and long-lasting antibody response and broad neutralizing activity against HIV, as requested under the Centers for Disease Control and Prevention and NIH solicitation seeking...
This is a $1,484,722.00 Cost Plus Fixed Fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Zymeron Corporation, a minority-owned small business located in Research Triangle Park, North Carolina. The contract was awarded under DARPA's Small Business Innovation Research (SBIR) program, Phase II, for the development of an "Automated Partial Occlusion for Truncal Hemorrhage Control" technology. This Phase II award builds upon earlier SBIR work and is...
Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...